S W Cowan-Jacob

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Structural biology of protein tyrosine kinases
    S W Cowan-Jacob
    Novartis Institutes for BioMedical Research, Lichtstrasse 35, WSJ 88 9 08a, Novartis Pharma AG, 4056 Basel, Switzerland
    Cell Mol Life Sci 63:2608-25. 2006
  2. ncbi The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation
    Sandra W Cowan-Jacob
    Discovery Technologies, Novartis Institutes for BioMedical Research, CH 4056 Basel, Switzerland
    Structure 13:861-71. 2005
  3. ncbi Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
    Sandra W Cowan-Jacob
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Acta Crystallogr D Biol Crystallogr 63:80-93. 2007
  4. ncbi Structural biology contributions to tyrosine kinase drug discovery
    Sandra W Cowan-Jacob
    Novartis Institutes of Biomedical Research, Novartis Pharma AG, Postfach, Basel, Switzerland
    Curr Opin Cell Biol 21:280-7. 2009
  5. ncbi The mode of action and the structure of a herbicide in complex with its target: binding of activated hydantocidin to the feedback regulation site of adenylosuccinate synthetase
    R Fonne-Pfister
    Pharmaceutical Division, Ciba Geigy Ltd, Basel, Switzerland
    Proc Natl Acad Sci U S A 93:9431-6. 1996
  6. ncbi Imatinib: a selective tyrosine kinase inhibitor
    P W Manley
    Novartis Pharma Ltd, Basel, Switzerland
    Eur J Cancer 38:S19-27. 2002
  7. ncbi Structures of adenylosuccinate synthetase from Triticum aestivum and Arabidopsis thaliana
    L Prade
    Novartis Pharma AG, Basel, CH 4056, Switzerland
    J Mol Biol 296:569-77. 2000
  8. ncbi Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells
    H Zhang
    Novartis Pharma AG, Oncology, Molecular Genetics, CH 4002 Basel, Switzerland
    J Biol Chem 275:11092-9. 2000

Collaborators

Detail Information

Publications8

  1. ncbi Structural biology of protein tyrosine kinases
    S W Cowan-Jacob
    Novartis Institutes for BioMedical Research, Lichtstrasse 35, WSJ 88 9 08a, Novartis Pharma AG, 4056 Basel, Switzerland
    Cell Mol Life Sci 63:2608-25. 2006
    ..This review gives a general overview of protein tyrosine kinase structural biology, including a discussion of the strengths and limitations of the investigative methods involved...
  2. ncbi The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation
    Sandra W Cowan-Jacob
    Discovery Technologies, Novartis Institutes for BioMedical Research, CH 4056 Basel, Switzerland
    Structure 13:861-71. 2005
    ..This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile...
  3. ncbi Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
    Sandra W Cowan-Jacob
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Acta Crystallogr D Biol Crystallogr 63:80-93. 2007
    ..These results are presented in a way which illustrates the approaches used to generate multiple structures, the type of information that can be gained and the way that this information is used to support drug discovery...
  4. ncbi Structural biology contributions to tyrosine kinase drug discovery
    Sandra W Cowan-Jacob
    Novartis Institutes of Biomedical Research, Novartis Pharma AG, Postfach, Basel, Switzerland
    Curr Opin Cell Biol 21:280-7. 2009
    ..This leads to a better understanding of how mutations lead to activation of kinases and resistance, in addition to providing opportunities for novel modes of targeting kinases...
  5. ncbi The mode of action and the structure of a herbicide in complex with its target: binding of activated hydantocidin to the feedback regulation site of adenylosuccinate synthetase
    R Fonne-Pfister
    Pharmaceutical Division, Ciba Geigy Ltd, Basel, Switzerland
    Proc Natl Acad Sci U S A 93:9431-6. 1996
    ..This work provides the first crystal structure of a herbicide-target complex reported to date...
  6. ncbi Imatinib: a selective tyrosine kinase inhibitor
    P W Manley
    Novartis Pharma Ltd, Basel, Switzerland
    Eur J Cancer 38:S19-27. 2002
    ..In this paper, the relationship between molecular biology and drug discovery methods, as utilized for the identification of anticancer drugs, will be illustrated...
  7. ncbi Structures of adenylosuccinate synthetase from Triticum aestivum and Arabidopsis thaliana
    L Prade
    Novartis Pharma AG, Basel, CH 4056, Switzerland
    J Mol Biol 296:569-77. 2000
    ..coli AdSS, exclusively activated by ligands at the IMP-binding site. The dimer interfaces show up to six hydrogen bonds and six salt-bridges more than in the E. coli structure, although the contact areas have approximately the same size...
  8. ncbi Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells
    H Zhang
    Novartis Pharma AG, Oncology, Molecular Genetics, CH 4002 Basel, Switzerland
    J Biol Chem 275:11092-9. 2000
    ..e. a hydrophobic pocket for the binding of proapoptotic proteins, rather than extended sequence homologies...